New efficacy data for Pfizer's 4-1BB, OX40 programs

Abstracts published ahead of next month's American Society of Clinical Oncology (ASCO) meeting included data for a pair of next-generation immuno-oncology programs from Pfizer Inc. (NYSE:PFE).

Read the full 269 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE